MARKET

EWTX

EWTX

Edgewise Therapeutics, Inc.
NASDAQ
40.60
+1.41
+3.60%
After Hours: 40.81 +0.21 +0.52% 17:20 09/30 EDT
OPEN
39.49
PREV CLOSE
39.19
HIGH
42.12
LOW
38.89
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
48.51
52 WEEK LOW
14.25
MARKET CAP
4.41B
P/E (TTM)
-21.9578
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EWTX last week (0921-0925)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
TipRanks · 5d ago
Edgewise Therapeutics Down Over 9%, on Pace for Largest Percent Decrease Since December 2025 -- Data Talk
Dow Jones · 09/23 17:55
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
TipRanks · 09/23 13:10
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)
TipRanks · 09/23 12:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owlet (OWLT), Celldex (CLDX) and Edgewise Therapeutics (EWTX)
TipRanks · 09/23 11:50
Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital
TipRanks · 09/23 11:35
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
PR Newswire · 09/22 11:00
More
About EWTX
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).

Webull offers Edgewise Therapeutics Inc stock information, including NASDAQ: EWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EWTX stock methods without spending real money on the virtual paper trading platform.